PCI Acquires Penn Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PCI Acquires Penn Pharma

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 8

Packaging Coordinators, Inc. (PCI) will acquire Penn Pharmaceutical Services Limited (Penn Pharma), which is headquartered in the United Kingdom and operates regional offices in Pennsylvania and Japan.  Penn Pharma’s drug development, manufacturing, and packaging services complement PCI’s clinical-trial and commercial-supply services. Recently, Penn Pharma opened a new manufacturing facility for the development and manufacturing of solid oral-dose products containing highly potent compounds. In 2014, Penn launched a capacity expansion project for large-scale commercial manufacturing and packaging. PCI also expanded both its global operations in North America and Europe and announced cold-chain infrastructure expansions for storage, logistics, and support for refrigerated packaging operations.  PCI will also open a North American storage and distribution facility for investigational products in September, 2014.

“With Penn Pharma’s services, we can partner with clients at the very earliest stages of drug development to support them with drug formulation, analytical development, drug manufacturing, clinical packaging, global distribution, and ultimately supporting the product’s commercial launch.  This addition expands our vision of lifecycle support from clinical trials through commercialization,” said Bill Mitchell, president and CEO of PCI, in a press release.

Source: PCI

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here